KemPharm, Inc. (KMPH)
(Delayed Data from NSDQ)
$1.37 USD
+0.06 (4.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.37 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Zevra Therapeutics, Inc. [KMPH]
Reports for Purchase
Showing records 1 - 20 ( 116 total )
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Two Posters Presented at WORLDSymposium for Arimoclomol in NPC
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Management Changes Reflect Maturing Company, Expecting Eventful 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Starts Phase 2 Trial KP1077 Trial in Idiopathic Hypersomnia
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Arimoclomol -Delay- Not Material; It?s Still All Upside For Us; Azstarys Rx Ramping; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
3Q22: Several Relatively Near-Term Events, Well-Funded & Capital Efficient
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
SDX Delivers Positive Phase 1 Single- Dose Cardiovascular Safety Results
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Azstarys Rx Ramping; Arimoclomol and KP1077 Clarity Coming; Tweak PT to $10 on Lower Azstarys, But Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
2Q22: Several Relatively Near-Term Events, Well-Funded & Capital Efficient
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Published Results Show Highly Favorable Safety and Abuse Profile of SDX
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Arimoclomol Ultra-Rare CNS Play Truly Looks Like a Free Call Option; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
1Q22: Acquires Arimoclomol from Orphazyme, SDX in Phase 1, Well Funded
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J